|
answer text |
<p>The National Institute for Health and Care Excellence (NICE) has advised that on
15 May 2019 it confirmed that it was able to recommend nusinersen for the treatment
of spinal muscular atrophy. In the announcement, NICE said the treatment would be
made available under the terms of the managed access agreement between NHS England
and NHS Improvement and Biogen. However, the full detail of the agreement was not
given in the announcement and NICE accepts this was misleading for some of the patient
population. NICE provided clarification at the earliest opportunity and has apologised
to individuals affected.</p>
|
|